Singapore, April 21 -- US-based Eli Lilly and Company, and Kelonia Therapeutics, Inc., a US-based clinical-stage biotechnology company pioneering in vivo gene delivery, have announced a definitive agreement for Lilly to acquire Kelonia.

Kelonia has developed a proprietary in vivo gene placement system (iGPS(R) ) that uses specially engineered lentiviral-based particles designed to efficiently and selectively enter T-cells inside the body, allowing the patient's own body to generate chimeric antigen receptor T-cell (CAR-T) therapies that can treat underlying disease.

Kelonia's lead programme, KLN-1010, is an investigational, one-time intravenous gene therapy that generates anti-B-cell maturation antigen (BCM...